Lyell to cut staff by 25%, CMO departs

2023-11-08

细胞疗法临床1期免疫疗法临床2期

Lyell Immunopharma disclosed that it is letting go of about a quarter of its workforce by year-end and has scaled down investment in certain early-stage research programmes, actions it says will allow it to fund operations through to 2027. Chief medical officer Tina Albertson is also leaving the company.

"As we continue to generate clinical data from our two lead programmes, we have also taken important steps toward reducing costs and manufacturing time for cell therapies through our proof-of-concept CAR T-cell manufacturing collaboration with Cellares and advances in our Epi-R P2 manufacturing process," stated CEO Lynn Seely. She added that the company has decided to prioritise investments in its clinical-stage programmes instead.

Last year's GSK bow-out

According to its website, the company is evaluating the CAR-T cell therapy LYL797 in Phase I for patients with ROR1-positive triple-negative breast cancer ROR1-positive triple-negative breast cancer or non-small-cell lung cancer. The second Phase I programme is LYL845, an autologous TIL therapy produced with Lyell's Epi-R epigenetic reprogramming protocol. Seely said Lyell remains on track to present initial data from each of its two lead Phase I projects next year.

The layoffs and pipeline prioritisation come roughly a year after GSK discontinued its development of drugs targeting NY-ESO-1, including the second-generation candidates incorporating Lyell's Epi-R technologies LYL132 and LYL331. When Lyell made the disclosure in October last year, it noted that GSK still remained a "significant stockholder" of the company.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构